gc-1118
mAbexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02352571)
Timeline
Indications
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650290 ↗
Also known as
- gc1118
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04077255 | Phase 2 | Sep 1, 2019 | National Cancer Center, Korea, Seoul National University |
| NCT03618667 | Phase 2 | Apr 30, 2018 | Sungkyunkwan University |
| NCT02352571 | Phase 1 | Jan 1, 2015 | Green Cross Corporation |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Green Cross Corporation | For profit | 1 | 1 | 1 | 2015 |
| National Cancer Center, Korea | Government | 1 | 1 | 1 | 2019 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Sungkyunkwan University | Academic/Hospital | 1 | 1 | 1 | 2018 |
4 organizations
Page 1 / 1